NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are ...

IGM Biosciences is laying off 100 workers as it shuts down two research projects, causing the Mountain View company's stock ...

Fintel reports that on January 13, 2025, JP Morgan upgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from ...

IGM Biosciences Inc (IGMS) stock saw a modest uptick, ending the day at $2 which represents a slight increase of $0.29 or 16.96% from the prior close of $1.71. The stock opened at $1.75 and touched a ...

Wedbush restated their neutral rating on shares of IGM Biosciences (NASDAQ:IGMS – Free Report) in a report issued on Friday morning, MarketBeat reports. Wedbush currently has a $3.00 target price on ...

IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from $12.00 to $2.00 in a research note issued to investors on Friday,Benzinga ...

Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold. Analyst Price Forecast Suggests 858.18% Upside As of December 23, 2024, ...

JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing ...

https://www.tipranks.com/news/the-fly/irhythm-price-target-raised-to-125-from-112-at-needham Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval, leading to a greater-than-50% drop in share price. Despite holding substantial liquid assets and a ...